Core Viewpoint - Baiyang Pharmaceutical has signed a deepening cooperation agreement with CSL, a global biotechnology leader, to exclusively promote, sell, and distribute CSL's human albumin product, Ambomab, in specific markets in China, enhancing the commercialization of blood products in the region [2][3]. Group 1: Partnership Details - The agreement expands the existing collaboration that began in 2018, now covering specific retail, broad market, and hospital markets in China [2]. - CSL has been a major supplier of human albumin in China since 1986, leveraging its extensive plasma collection network [2]. Group 2: Market Context - The human albumin market in China is the largest therapeutic drug market, exceeding 30 billion yuan, with a long-term trend of import dominance [3]. - In 2024, the import of human albumin products is expected to grow by approximately 17%, with imports accounting for nearly 70% of the market [3]. Group 3: Product Advantages - Ambomab is specifically designed for the Chinese market, with a key advantage of being stored at temperatures not exceeding 30°C, reducing reliance on complex cold chain logistics and improving drug accessibility [3]. - The collaboration is expected to create strong synergies in the liver disease sector, addressing the needs of a large patient population in China [3].
百洋医药与杰特贝林就人血白蛋白「安博美」深化合作，发力肝病领域协同效应